GlassScriptPhysician profile
Kathleen A Messenger
NPI 1174574701
$16,286.42
in general payments reported to CMS, 2019-2025
46 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,591 · 2020: $1,453 · 2021: $2,369 · 2022: $2,658 · 2023: $2,657 · 2024: $3,007 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,096 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,095.89 |
| Education | $118.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,298.60 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,679.74 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Biogen, INC. | $1,090.61 | 2019-2025 | Vumerity, Tysabri |
| Pfizer INC. | $1,016.11 | 2023-2025 | |
| Lilly USA, LLC | $1,000.27 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Novartis Pharmaceuticals Corporation | $930.81 | 2020-2025 | |
| Ucb, INC. | $639.23 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Genzyme Corporation | $611.32 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $597.11 | 2021-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $571.62 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $537.04 | 2020-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $496.66 | 2019-2024 | Nuplazid |
| Amgen INC. | $488.36 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $458.94 | 2024-2025 | Purified Cortrophin Gel |
| Avanir Pharmaceuticals, INC. | $439.67 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Messenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.